feed,title,long_url,short_url
GN:S:RL,Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers USA - English - USA - English - PR Newswire,https://www.prnewswire.com/news-releases/insilico-medicine-expands-synthetic-lethality-portfolio-with-nomination-of-a-preclinical-candidate-targeting-mat2a-for-the-treatment-of-mtap-deleted-cancers-301540618.html,https://prn.to/3NaT8Mr
